Lanean...
Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis
Chronic myelogenous leukemia (CML) is caused by the constitutively active tyrosine kinase Bcr-Abl and treated with the tyrosine kinase inhibitor (TKI) imatinib. However, emerging TKI resistance prevents complete cure. Therefore, alternative strategies targeting regulatory modules of Bcr-Abl in addit...
Gorde:
| Egile Nagusiak: | , , , , , , , , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Cell Press
2011
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3202669/ https://ncbi.nlm.nih.gov/pubmed/22000011 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cell.2011.08.046 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|